Clinical Trial Launch, Acquisition, Conference Schedule, Reimbursement Rates Impact, and Product Approval - Research Report on NewLink, Addus HomeCare, Wright Medical, Alliance, and USANA PR Newswire NEW YORK, January 6, 2014 NEW YORK, January 6, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting NewLink Genetics Corporation (NASDAQ: NLNK), Addus HomeCare Corporation (NASDAQ: ADUS), Wright Medical Group, Inc. (NASDAQ: WMGI), Alliance HealthCare Services, Inc. (NASDAQ: AIQ), and USANA Health Sciences, Inc. (NYSE: USNA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. NewLink Genetics Corporation Research Report On December 19, 2013, NewLink Genetics Corporation (NewLink) announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer. "HyperAcute Renal represents our sixth HyperAcute immunotherapy to advance into clinic," said Dr. Charles Link, Chairman and CEO of NewLink. "As with pancreatic cancer and algenpantucel-L, we believe renal cell cancer may also be particularly well suited to HyperAcute Renal immunotherapy. We continue to develop new HyperAcute immunotherapies as we approach the initial interim analysis of our pivotal IMPRESS trial for algenpantucel-L, our lead HyperAcute immunotherapy for patients with resected pancreatic cancer." The Company notified that the Phase 1 dose-escalation study aims primarily to determine the safety of HyperAcute Renal immunotherapy cells administered by intradermal injection in up to 20 patients with recurrent or refractory, metastatic clear-cell renal cancer. The Full Research Report on NewLink Genetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/c592_NLNK Addus HomeCare Corporation Research Report On December 6, 2013, Addus HomeCare Corporation (Addus HomeCare) announced that it has closed on its acquisition of the previously announced purchase of substantially all of the assets of Coordinated Home Health Care, LLC (Coordinated Home Health Care) and certain of its subsidiaries, effective as of December 1, 2013. Addus HomeCare notified that the acquisition includes 15 offices in southern New Mexico and further expands the Company's presence in the state. "We are pleased to complete the purchase of Coordinated Home Health as it substantially expands or footprint in New Mexico, a state which is on the forefront of transitioning its Medicaid long term care programs to managed care," said Mark Heaney, President and CEO of Addus HomeCare. The Full Research Report on Addus Homecare Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2b69_ADUS Wright Medical Group, Inc. Research Report On December 18, 2013, Wright Medical Group, Inc. (Wright Medical) announced its participation at the 32^nd Annual J.P. Morgan Healthcare Conference on January 13, 2014 at the Westin St. Francis Hotel in San Francisco, California. The Company informed that it's President and CEO, Robert Palmisano, is scheduled to make the presentation at 2:30 p.m. PT on the aforesaid date. Wright Medical stated that the live audio webcast of the conference presentation and replay of the same will be accessible through its Investor Relations website. The Full Research Report on Wright Medical Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/1782_WMGI Alliance HealthCare Services, Inc. Research Report On December 12, 2013, Alliance HealthCare Services, Inc. (Alliance) announced additional information regarding the potential impact of the final 2014 Medicare reimbursement rates, which were issued on November 27, 2013 by the Centers for Medicare and Medicaid Studies (CMS). The Company notified that the total impact to Alliance is a predicted reduction of c.$2.8 million in Medicare reimbursement, based on 2013 estimated volume data. "We are pleased to receive the final rule, which now allows us to more accurately plan for the impact in 2014. While slightly more than our initial impact expectations of $2 million, this change in reimbursement represents approximately 2% of our full year 2013 Adjusted EBITDA guidance range. This is a manageable amount and will not hinder our ability to do business or our focus on expanding our relationships and providing added value to our hospital partners," said Howard Aihara, Executive Vice President and CFO of Alliance. The Full Research Report on Alliance HealthCare Services, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7913_AIQ USANA Health Sciences, Inc. Research Report On December 5, 2013, USANA Health Sciences, Inc. (USANA) announced that one of its top-rated supplements, newly upgraded dairy- and sugar-free USANA Probiotic, has been evaluated and approved by ConsumerLab.com LLC (ConsumerLab.com), a company that independently tests health products for purity, disintegration and strength. According to the Company, ConsumerLab.com also approved USANA Essentials, Body Rox, Usanimals, and CoQuinone 30 supplements. "It's an honor to receive product certification by a reputable third-party organization such as ConsumerLab.com," said Dan Macuga, Chief Communications Officer of USANA. "It demonstrates our resilient commitment to producing effective and reliable products for consumers." The Full Research Report on USANA Health Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ee40_USNA EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Trial Launch, Acquisition, Conference Schedule, Reimbursement Rates Impact, and Product Approval - Research Report on
Press spacebar to pause and continue. Press esc to stop.